Allergan Inc (AGN) 166.00 $AGN
Data on Novartis' Onbrez Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 5:10PM CDT
Novartis (NVS) announced positive top-line results from a phase IV study, INSTEAD, on Onbrez Breezhaler.
Label Expansion for Roche's HPV Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 4:30PM CDT
Roche (RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved its cobas Human Papillomavirus (HPV) Test for use as a first-line primary screening test for cervical cancer in women aged 25 and above.
Why Shire (SHPG) Stock Is Surging Today
at The Street - Mon Apr 28, 2:55PM CDT
Shares of Shire (SHPG) are higher after Allergan (AGN), facing an unsolicited bid from Valeant Pharmaceuticals (VRTX), is preparing to approach Shire again about a potential takeover after being rebuffed in recent months..
Pfizer still pursuing AstraZeneca after 2nd rebuff
By DANICA KIRKA and LINDA A. JOHNSON - AP - Mon Apr 28, 4:10PM CDT
LONDON (AP) — Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.
Forest Laboratories Inks $1.4B Deal for Furiex
at The Street - Mon Apr 28, 10:40AM CDT
Forest Laboratories said Monday it has a deal to acquire Furiex Pharmaceuticals for upward of $1.4 billion, boosting its gastroenterology unit amid a wave of consolidation in the drug business.
Global Macular Edema Therapeutics Pipeline Review 2014 - Key Analysis of 8 Companies & 11 Drug Profiles
M2 - Mon Apr 28, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/799c57/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Taiwan Liposome Company, Ltd. - Ampio Pharmaceuticals, Inc. - AlphaMab Co., Ltd Drug Profiles - ranibizumab - interferon beta-1a - betamethasone - beclomethasone dipropionate - trientine hydrochloride - dexamethasone SR - dexamethasone SR - PARP Inhibitors - DMI-5207 - PRM-167 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/79...ular_edema
Global Rosacea Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwn2d4/rosacea) has announced the addition of the "Global Rosacea Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Allergan, Inc. - Merck & Co., Inc. - Novartis AG - Amorepacific Corporation - Galderma S.A. - Paratek Pharmaceuticals, Inc. - Celgene Corporation - Paloma Pharmaceuticals, Inc. - Foamix Ltd. - Gene Signal International SA - Cutanea Life Sciences - Sol-Gel Technologies Ltd. - Signum Biosciences, Inc. - Advancell - Delenex Therapeutics AG - TWi Pharmaceuticals, Inc. - Dermira Inc. Drug Profiles - omiganan pentahydrochloride - ivermectin - sirolimus - apremilast - DRM-02 - (betamethasone calcipotriene) - oxymetazoline hydrochloride - benzoyl peroxide - DER-45EV - PAC-14028 - PDI-320 - AC-701 - aganirsen - cromolyn sodium - laropiprant - sarecycline hydrochloride - SIG-990 - DLX-1008 - ANs-29 - GM-1111 - SIG-989 - SIG-1191 - SIG-1192 - P-529 - minocycline Gel For more information visit http://www.researchandmarkets.com/research/mwn2d4/rosacea
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
IBD 50: Valeant Taking The Buyout Route To Growth
at Investor's Business Daily - Fri Apr 25, 5:42PM CDT
Valeant Pharmaceuticals (VRX) is using buyouts to boost its business. The diversified Canadian drugmaker has made a boatload of buyouts, including a couple of big ones. In August, Valeant wrapped up its $8.7 billion acquisition of eye-care giant...
Wachtell Sees 'Threat' in Ackman's Allergan Bid
at The Street - Fri Apr 25, 3:48PM CDT
Activist investor critic Wachtell Lipton said hedge fund Pershing Square Capital Management's role in Valeant Pharmaceuticals $45 billion bid for Allergan was a new threat to Corporate America.
AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 3:45PM CDT
AbbVie (ABBV) surpassed expectations in the first quarter on the back of strong Humira sales.
Novartis Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 11:00AM CDT
Novartis (NVS) reported first quarter 2014 earnings per share of $1.21. Core earnings per share came in at $1.31, up 6% from the year-ago period but missed the Zacks Consensus Estimate of $1.33.
Prestige Brands Acquires Insight for $750M
at The Street - Fri Apr 25, 10:52AM CDT
Deal for feminine care product maker caps an active week for pharmaceutical mergers.
AstraZeneca Misses Earnings But Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:30AM CDT
AstraZeneca's first-quarter 2014 core earnings of $1.17 per American Depositary Share missed the Zacks Consensus Estimate of $1.20.
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.
Update on Glaxo/Theravance's COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:33PM CDT
Glaxo (GSK) and partner Theravance (THRX) announced the initiation of a phase III study on Relvar Ellipta.
Inside Valeant Pharmaceuticals' Bid for Allergan
Brendan Mathews, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Earlier this week, Valeant Pharmaceutical made a public offer to buy rival Allergan . Let's review the major questions this huge potential deal raises, to see whether it's a smart move – and whether or not it'll actually happen. What is...
Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.
Data on Novartis' Onbrez Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 5:10PM CDT
Novartis (NVS) announced positive top-line results from a phase IV study, INSTEAD, on Onbrez Breezhaler.
Label Expansion for Roche's HPV Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 4:30PM CDT
Roche (RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved its cobas Human Papillomavirus (HPV) Test for use as a first-line primary screening test for cervical cancer in women aged 25 and above.
Why Shire (SHPG) Stock Is Surging Today
at The Street - Mon Apr 28, 2:55PM CDT
Shares of Shire (SHPG) are higher after Allergan (AGN), facing an unsolicited bid from Valeant Pharmaceuticals (VRTX), is preparing to approach Shire again about a potential takeover after being rebuffed in recent months..
Pfizer still pursuing AstraZeneca after 2nd rebuff
By DANICA KIRKA and LINDA A. JOHNSON - AP - Mon Apr 28, 4:10PM CDT
LONDON (AP) — Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.
Forest Laboratories Inks $1.4B Deal for Furiex
at The Street - Mon Apr 28, 10:40AM CDT
Forest Laboratories said Monday it has a deal to acquire Furiex Pharmaceuticals for upward of $1.4 billion, boosting its gastroenterology unit amid a wave of consolidation in the drug business.
Global Macular Edema Therapeutics Pipeline Review 2014 - Key Analysis of 8 Companies & 11 Drug Profiles
M2 - Mon Apr 28, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/799c57/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Taiwan Liposome Company, Ltd. - Ampio Pharmaceuticals, Inc. - AlphaMab Co., Ltd Drug Profiles - ranibizumab - interferon beta-1a - betamethasone - beclomethasone dipropionate - trientine hydrochloride - dexamethasone SR - dexamethasone SR - PARP Inhibitors - DMI-5207 - PRM-167 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/79...ular_edema
Global Rosacea Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwn2d4/rosacea) has announced the addition of the "Global Rosacea Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Allergan, Inc. - Merck & Co., Inc. - Novartis AG - Amorepacific Corporation - Galderma S.A. - Paratek Pharmaceuticals, Inc. - Celgene Corporation - Paloma Pharmaceuticals, Inc. - Foamix Ltd. - Gene Signal International SA - Cutanea Life Sciences - Sol-Gel Technologies Ltd. - Signum Biosciences, Inc. - Advancell - Delenex Therapeutics AG - TWi Pharmaceuticals, Inc. - Dermira Inc. Drug Profiles - omiganan pentahydrochloride - ivermectin - sirolimus - apremilast - DRM-02 - (betamethasone calcipotriene) - oxymetazoline hydrochloride - benzoyl peroxide - DER-45EV - PAC-14028 - PDI-320 - AC-701 - aganirsen - cromolyn sodium - laropiprant - sarecycline hydrochloride - SIG-990 - DLX-1008 - ANs-29 - GM-1111 - SIG-989 - SIG-1191 - SIG-1192 - P-529 - minocycline Gel For more information visit http://www.researchandmarkets.com/research/mwn2d4/rosacea
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
IBD 50: Valeant Taking The Buyout Route To Growth
at Investor's Business Daily - Fri Apr 25, 5:42PM CDT
Valeant Pharmaceuticals (VRX) is using buyouts to boost its business. The diversified Canadian drugmaker has made a boatload of buyouts, including a couple of big ones. In August, Valeant wrapped up its $8.7 billion acquisition of eye-care giant...
Wachtell Sees 'Threat' in Ackman's Allergan Bid
at The Street - Fri Apr 25, 3:48PM CDT
Activist investor critic Wachtell Lipton said hedge fund Pershing Square Capital Management's role in Valeant Pharmaceuticals $45 billion bid for Allergan was a new threat to Corporate America.
AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 3:45PM CDT
AbbVie (ABBV) surpassed expectations in the first quarter on the back of strong Humira sales.
Novartis Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 11:00AM CDT
Novartis (NVS) reported first quarter 2014 earnings per share of $1.21. Core earnings per share came in at $1.31, up 6% from the year-ago period but missed the Zacks Consensus Estimate of $1.33.
Prestige Brands Acquires Insight for $750M
at The Street - Fri Apr 25, 10:52AM CDT
Deal for feminine care product maker caps an active week for pharmaceutical mergers.
AstraZeneca Misses Earnings But Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:30AM CDT
AstraZeneca's first-quarter 2014 core earnings of $1.17 per American Depositary Share missed the Zacks Consensus Estimate of $1.20.
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.
Update on Glaxo/Theravance's COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:33PM CDT
Glaxo (GSK) and partner Theravance (THRX) announced the initiation of a phase III study on Relvar Ellipta.
Inside Valeant Pharmaceuticals' Bid for Allergan
Brendan Mathews, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Earlier this week, Valeant Pharmaceutical made a public offer to buy rival Allergan . Let's review the major questions this huge potential deal raises, to see whether it's a smart move – and whether or not it'll actually happen. What is...
Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.
